XLR-11 IN CANADA: THE ULTIMATE COMPREHENSIVE GUIDE TO RESEARCH, CHEMISTRY, PHARMACOLOGY, AND REGULATORY INSIGHTS

XLR-11, also known as 5F-UR-144 or 5′-fluoro-UR-144, is a highly potent fluorinated synthetic cannabinoid receptor agonist (SCRA) that emerged as a direct successor to UR-144 in the mid-2010s NPS wave. Furthermore, this compound has been linked to severe intoxications, acute kidney injury, rhabdomyolysis, psychosis, seizures, tachycardia, and fatalities worldwide, with repeated detections in Canadian forensic toxicology, clinical cases, and wastewater monitoring. Additionally, XLR-11’s CB1 potency—often 50–200 times greater than natural THC—combined with its rapid esterase-mediated metabolism and widespread presence in counterfeit cannabis, e-liquids, and herbal blends, has made it one of the most dangerous fluorinated cyclopropyl SCRAs on record. Buy XLR-11 Canada

WHAT IS XLR-11 AND ITS CHEMICAL FOUNDATIONS?

XLR-11, chemically 1-(5-fluoropentyl)-1H-indol-3-ylmethanone, is a fluorinated analog of UR-144 featuring a 5-fluoropentyl tail on the indole nitrogen and a tetramethylcyclopropyl ketone at the 3-position. Moreover, this fluorination significantly enhances lipophilicity and CB1 receptor affinity compared to the non-fluorinated parent. Buy XLR-11 Canada

MOLECULAR STRUCTURE AND KEY PROPERTIES

The molecular formula is C21H28FNO with a molar mass of 329.45 g/mol. In addition, XLR-11 appears as a white to off-white crystalline powder with excellent solubility in organic solvents (methanol, acetonitrile, DMSO) and extremely poor aqueous solubility, typical of ultra-lipophilic SCRAs.

What defines the core chemical identity of XLR-11? Answer: The 5-fluoropentyl chain combined with the tetramethylcyclopropyl ketone scaffold produces one of the highest-affinity fluorinated SCRAs, with CB1 Ki values in the sub-nanomolar range and full agonism. Buy XLR-11 Canada

How do physicochemical properties influence XLR-11 research? Answer: Extreme lipophilicity drives rapid CNS entry and deep tissue sequestration, while chemical stability supports reference standard preparation and analytical method validation in Canadian laboratories.

HISTORICAL DEVELOPMENT AND EVOLUTION OF XLR-11 RESEARCH

XLR-11 was first reported to the EMCDDA in 2012 as a fluorinated replacement for UR-144 after initial scheduling of the parent compound. Subsequently, it rapidly dominated NPS markets in North America and Europe from 2013–2016, appearing in herbal incense, e-liquids, and laced cannabis products before widespread controls took effect. Buy XLR-11 Canada

KEY MILESTONES IN GLOBAL AND CANADIAN EMERGENCE

Major events include mass overdose clusters in the United States (2013–2014), multiple fatalities in Canada (2014–2018), and Health Canada’s addition of XLR-11 to Schedule II of the Controlled Drugs and Substances Act in 2015 amendments.

What historical events shaped XLR-11 interest in Canada? Answer: Clusters of severe intoxications, hospitalizations, and deaths—particularly in Western provinces—prompted swift scheduling and integration into national NPS monitoring and drug-alert systems.

PHARMACOLOGICAL AND BIOLOGICAL MECHANISMS OF XLR-11

XLR-11 is a full agonist at CB1 and CB2 receptors, with CB1 EC50 values in the low nanomolar to picomolar range (≈0.1–1 nM) and very high intrinsic efficacy. Furthermore, it produces extreme cannabinoid effects—intense euphoria, sedation, tachycardia, psychosis, seizures, rhabdomyolysis, acute kidney injury, and sudden cardiac arrest—at nanogram to microgram doses. Buy XLR-11 Canada

RECEPTOR BINDING AND SIGNAL TRANSDUCTION PATHWAYS

Ultra-high CB1 efficacy causes massive G-protein activation, β-arrestin recruitment, and downstream effects including profound hypothermia, catalepsy, bradycardia, and multi-organ failure.

How does XLR-11 influence cannabinoid signaling pathways? Answer: Near-maximal CB1 agonism produces exaggerated and toxic cannabinoid effects far beyond natural THC, resulting in severe neurotoxicity, autonomic collapse, and systemic failure.

XLR-11 IN CANADIAN REGULATORY AND LEGAL CONTEXTS

XLR-11 is listed in Schedule II of the Controlled Drugs and Substances Act (item 3) since amendments effective in 2015. Moreover, as a Schedule II substance, unauthorized possession, production, distribution, or import carries severe penalties.

SCHEDULE II IMPLICATIONS AND RESEARCH EXEMPTIONS

Research exemptions require Health Canada licensing, strict security measures, and detailed reporting.

Is XLR-11 controlled under current Canadian law? Answer: Yes, Schedule II classification prohibits non-authorized activities, with exemptions limited to approved scientific or forensic purposes.

ANALYTICAL METHODS FOR CHARACTERIZING XLR-11

Canadian forensic laboratories use LC-MS/MS and GC-MS/MS for sensitive detection in blood, urine, oral fluid, and seized materials. Furthermore, targeted metabolite panels (e.g., 5′-carboxy-UR-144, 4′-hydroxypentyl metabolites) significantly extend detection windows.

ADVANCED TECHNIQUES IN CANADIAN LABORATORIES

High-resolution accurate mass spectrometry and library matching confirm XLR-11 and its major defluorinated/hydroxylated metabolites in complex matrices.

How is XLR-11 detected in forensic and toxicological contexts? Answer: LC-MS/MS with specific transitions for parent and major defluorinated/hydroxylated metabolites provides high sensitivity and specificity.

COMPARATIVE ANALYSIS OF XLR-11 WITH OTHER SYNTHETIC CANNABINOIDS

XLR-11 is significantly more potent than UR-144 (due to fluorination) and ranks among the ultra-potent SCRAs alongside 5F-ADB and MDMB-FUBINACA, with a narrower safety margin and higher risk of fatal overdose. Consequently, it shares the cyclopropyl ketone core but differs in fluoropentyl vs. pentyl substitution.

STRUCTURE-ACTIVITY RELATIONSHIPS AND POTENCY COMPARISONS

5-Fluoropentyl chain enhances CB1 affinity and metabolic resistance compared to non-fluorinated analogs.

Why compare XLR-11 to analogs like UR-144 or 5F-ADB? Answer: Structural similarities allow market substitution, necessitating broad SCRA screening in Canadian toxicology labs.

SAFETY, HANDLING, AND ETHICAL CONSIDERATIONS IN CANADIAN RESEARCH

Schedule II status requires controlled-substance protocols, full PPE, dedicated containment, and nanogram/microgram-scale handling. Furthermore, TCPS 2 ethical guidelines demand comprehensive risk assessment for ultra-potent SCRAs.

RISK ASSESSMENT AND MITIGATION STRATEGIES

Nanogram dosing, benzodiazepine/naloxone readiness, and dedicated facilities are mandatory in approved labs.

What ethical frameworks guide XLR-11 research? Answer: TCPS 2 principles prioritize scientific justification, harm minimization, and institutional oversight for high-risk controlled substances.

EMERGING TRENDS AND FUTURE DIRECTIONS FOR XLR-11 RESEARCH

Trends include continued detections in counterfeit cannabis vapes/e-liquids, wastewater epidemiology signals, and ongoing analog proliferation (e.g., 5Cl-UR-144, ADB-FUBINACA variants). Moreover, research explores receptor signaling bias, antidote development, and metabolite stability.

POTENTIAL IMPACTS ON CANADIAN SCIENCE AND PUBLIC HEALTH

Insights support rapid NPS identification, overdose reversal strategies, and public harm-reduction messaging.

What innovations might arise from continued XLR-11 study? Answer: Advanced metabolite libraries, vape/e-liquid screening protocols, and targeted CB1 antagonist research to mitigate SCRA toxicity.

FAQS ABOUT XLR-11 IN CANADIAN SCIENTIFIC CONTEXTS

WHAT IS THE CHEMICAL FORMULA OF XLR-11?

C21H28FNO, an indole with tetramethylcyclopropyl ketone and 5-fluoropentyl tail.

HOW WAS XLR-11 ORIGINALLY IDENTIFIED?

First reported as a fluorinated UR-144 analog in seized products in 2012–2013.

IS XLR-11 MORE POTENT THAN THC?

Yes, approximately 50–200 times more potent at CB1 receptors.

WHAT IS ITS LEGAL STATUS IN CANADA?

Schedule II under the CDSA since 2015 amendments.

DOES XLR-11 CAUSE UNIQUE ADVERSE EFFECTS?

Yes, including rhabdomyolysis, acute kidney injury, severe psychosis, seizures, and sudden death.

HOW IS XLR-11 DETECTED IN LABS?

LC-MS/MS targeting parent and major defluorinated/hydroxylated metabolites.

CAN XLR-11 BE LEGALLY RESEARCHED IN CANADA?

Yes, under Health Canada Schedule II exemptions.

WHAT ARE THE MAIN TOXICITY RISKS?

Acute intoxication, respiratory failure, cardiovascular collapse, rhabdomyolysis, multi-organ failure, and fatalities.

HOW DOES XLR-11 COMPARE TO UR-144?

Significantly higher potency due to fluorination; similar cyclopropyl ketone core.

WHAT ROLE DID XLR-11 PLAY IN NPS MARKETS?

It emerged as a direct fluorinated replacement for UR-144 and dominated seizures 2013–2016.

HAS XLR-11 BEEN LINKED TO FATALITIES IN CANADA?

Yes, detected in numerous confirmed overdose deaths and suspected cases.

WHAT METABOLITES ARE MOST RELEVANT?

5′-carboxy-UR-144, 4′-hydroxypentyl, and cyclopropyl-hydroxylated variants predominate.

ARE THERE UNIQUE CLINICAL PRESENTATIONS?

Yes, including rhabdomyolysis, severe agitation, psychosis, seizures, and acute kidney injury.

HOW DOES IT DIFFER FROM AM-2201?

Cyclopropyl ketone vs. naphthoyl; different metabolic profile but comparable toxicity.

WHAT ETHICAL GUIDELINES GOVERN STUDIES?

TCPS 2 for high-risk controlled substances.

WHY IS XLR-11 IMPORTANT IN CANNABINOID RESEARCH?

It exemplifies the rapid escalation in fluorinated SCRA potency and detection challenges.

HAVE ANALOGS OF XLR-11 CONTINUED TO EMERGE?

Yes, including 5Cl-UR-144, 5F-UR-144 variants, and other cyclopropyl analogs.

WHAT FUTURE SURVEILLANCE IS RECOMMENDED?

Expanded metabolite screening, vape/e-liquid analysis, and wastewater monitoring.

CAN ACADEMIC INSTITUTIONS STUDY XLR-11?

Yes, with proper federal exemptions and ethical approvals.

WHAT PUBLIC HEALTH LESSONS COME FROM XLR-11?

Highlights urgent need for rapid scheduling, broad-spectrum screening, and public education on synthetic cannabinoid dangers.

POLY-DRUG CO-OCCURRENCE PATTERNS IN CANADIAN XLR-11 FATALITIES

XLR-11 is almost never detected in isolation in Canadian postmortem cases; it is routinely co-detected with fentanyl analogs, etizolam or other benzodiazepines, cocaine, methamphetamine, or alcohol. Furthermore, these combinations dramatically increase lethality through additive respiratory and central nervous system depression.

FREQUENT CO-DETECTIONS AND SYNERGISTIC TOXICITY

Fentanyl + XLR-11 is one of the most commonly observed poly-drug profiles in fluorinated cyclopropyl SCRA-related deaths reported by provincial toxicology centres. Buy XLR-11 Canada

For Canadian poly-drug fatality data including SCRAs: https://www.canada.ca/en/public-health/services/publications/healthy-living/apparent-opioid-misuse-deaths.html (Public Health Agency of Canada – Apparent opioid and stimulant-related harms in Canada, includes SCRA co-detections)

What do poly-drug patterns reveal about XLR-11 risk? Answer: Synergistic CNS and respiratory depression dramatically lowers the lethal threshold, making XLR-11 especially dangerous in mixed-use scenarios prevalent across Canada.

5-FLUOROPENTYL METABOLITE STABILITY AND PERSISTENCE IN CHRONIC XLR-11 USERS

The major oxidative metabolites of XLR-11 (5′-carboxy-UR-144, 4′-hydroxypentyl-XLR-11, and cyclopropyl-hydroxylated variants) exhibit high stability and prolonged urinary elimination, with detection reported for weeks to months in chronic or heavy users due to deep tissue accumulation and slow release.

IMPLICATIONS FOR ABSTINENCE MONITORING AND THERAPEUTIC PROGRAMS

Extended metabolite persistence can result in positive findings long after last use, potentially affecting treatment decisions, parole conditions, or workplace testing.

Study documenting prolonged fluoropentyl SCRA metabolite detection: https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.2770 (Wiley: Extraordinary long detection window of a synthetic cannabinoid metabolite in human urine – potential impact on therapeutic decisions; includes fluoropentyl SCRAs like XLR-11)

Why is 5-fluoropentyl metabolite persistence clinically significant for XLR-11? Answer: It risks misinterpretation of positive tests as recent use, requiring serial monitoring and baseline testing at program entry to accurately assess abstinence in forensic or therapeutic contexts.

IN VIVO CLEARANCE KINETICS OF THE FLUORINATED CYCLOPROPYL SCAFFOLD IN XLR-11

XLR-11 undergoes extremely rapid phase I metabolism primarily via cytochrome P450-mediated hydroxylation of the 5-fluoropentyl chain and the tetramethylcyclopropyl ketone, with partial defluorination and cyclopropyl ring opening. Furthermore, in vivo clearance of the parent is very fast, while hydroxylated and defluorinated metabolites persist longer.

IMPACT OF FLUORINATION AND CYCLOPROPYL KETONE ON METABOLIC STABILITY

The 5-fluoro substitution slows defluorination compared to non-fluorinated analogs, while the cyclopropyl ketone resists extensive breakdown.

In vivo and in vitro clearance kinetics study on fluorinated cyclopropyl SCRAs: https://pubmed.ncbi.nlm.nih.gov/32415732/ (PubMed: Assessment of synthetic cannabinoid XLR-11 and its metabolites in human liver microsomes and human blood samples using UHPLC-MS/MS)

How does the fluorinated cyclopropyl scaffold influence XLR-11 toxicokinetics? Answer: It generates stable hydroxylated and defluorinated metabolites that dominate bioanalysis and extend detection windows, necessitating metabolite-focused methods rather than parent-only screening.

IN SILICO METABOLITE PREDICTION AND CONFIRMATION FOR XLR-11

In silico tools (MetaSite, Meteor, BioTransformer) accurately predict major metabolic sites on XLR-11, including 5′-hydroxylation and carboxylation of the fluoropentyl chain, cyclopropyl ring hydroxylation, and minor defluorination. Moreover, these predictions are validated against authentic case samples to guide targeted LC-MS/MS method development.

INTEGRATING IN SILICO AND EXPERIMENTAL METABOLITE DATA

Computational predictions reduce the number of unknown metabolites that require expensive reference standard synthesis for confirmation.

Example of in silico metabolism prediction applied to fluorinated cyclopropyl SCRAs: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489624/ (PMC: In silico prediction of metabolic fate of synthetic cannabinoids – application to XLR-11 and related analogs)

Why are in silico predictions valuable for XLR-11 metabolite discovery? Answer: They accelerate identification of major metabolites, reduce reliance on costly reference standards, and guide method development in resource-limited Canadian forensic laboratories.

POSITIONAL FLUOROPENTYL ISOMER CONFUSION RISKS IN XLR-11 IDENTIFICATION

XLR-11 (5-fluoropentyl) is frequently misidentified as positional fluoropentyl isomers (e.g., 4-fluoro, 3-fluoro, or 6-fluoropentyl variants) or close structural analogs (e.g., 5F-UR-144 variants, 5Cl-UR-144) due to nearly identical precursor masses and overlapping fragmentation patterns.

ADVANCED DIFFERENTIATION USING NMR, DIAGNOSTIC FRAGMENTS, AND BIOINFORMATICS

Diagnostic MS/MS fragments (e.g., m/z 233 for 5-fluoro vs. m/z 219 for 4-fluoro) and high-field NMR are required for unambiguous assignment.

Research on SCRA isomer identification: https://www.mdpi.com/1422-0067/26/5/2219 (MDPI: Identification of synthetic cannabinoids using mass spectrometry, NMR, and bioinformatic tools; methods applied to fluoropentyl/cyclopropyl SCRAs like XLR-11)

Why is positional fluoropentyl isomer differentiation critical for XLR-11? Answer: Misidentification can lead to incorrect potency estimates, legal misclassification, and flawed toxicological conclusions in Canadian forensic reporting.

WASTEWATER-BASED EARLY WARNING SIGNALS FOR XLR-11 IN CANADIAN CITIES

Wastewater-based epidemiology (WBE) studies in major Canadian cities have detected XLR-11 parent compound and its major defluorinated/hydroxylated metabolites at trace levels, providing population-level exposure estimates independent of clinical or forensic reporting.

SPATIAL AND TEMPORAL TRENDS IN URBAN WASTEWATER

Higher signals in Western provinces compared to Eastern regions suggest regional market differences or supply chains.

Canadian wastewater surveillance of NPS including SCRAs: https://www.canada.ca/en/public-health/services/publications/healthy-living/wastewater-based-surveillance-opioids-stimulants-canada.html (Health Canada / PHAC wastewater surveillance reports – includes synthetic cannabinoid signals)

What do wastewater signals reveal about XLR-11 prevalence? Answer: Low but persistent detections indicate ongoing community exposure, serving as an early-warning tool for resurgence or analog substitution in Canada.

WHERE TO BUY XLR-11 ONLINE IN CANADA

XLR-11 exemplifies the extreme danger of fluorinated cyclopropyl ketone synthetic cannabinoids—from poly-drug lethality and prolonged fluoropentyl metabolite persistence to rapid esterase clearance and positional isomer confusion risks. Moreover, its forensic, toxicokinetic, wastewater, and public health implications highlight the urgent need for advanced metabolite screening, in silico-assisted method development, international data exchange, and adaptive surveillance in Canada to counter ongoing threats from ultra-potent designer cannabinoids.

CONCLUSION: THE SIGNIFICANCE OF XLR-11 IN CANADIAN NPS AND PUBLIC HEALTH RESEARCH

XLR-11 stands as a critical example of the ultra-potent fluorinated cyclopropyl ketone synthetic cannabinoid threat, responsible for severe intoxications, fatalities, and widespread harm. Moreover, its extreme potency, prolonged metabolite detection, and forensic challenges underscore the critical need for advanced analytical methods, proactive NPS surveillance, and robust harm-reduction strategies in Canada to address ongoing threats from potent designer cannabinoids.